Spermatogonial Stem Cells: An Alternate Source of Pluripotent Stem Cells for Regenerative Medicine

Liz Simon¹, Marie-Claude Hofmann² and Paul S. Cooke³

¹Department of Biomedical Sciences, College of Veterinary Medicine, Nursing and Allied Health, Tuskegee University, Tuskegee, AL
²Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL
³Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL
USA

1. Introduction

There is immense scientific and medical interest in stem cells as a potential source material for regenerative medicine to replace or restore lost, damaged, or aging cells, tissues or organs (Mason and Dunnill 2008). The ideal stem cell candidate for regenerative medicine is a pluripotent stem cell that is easily obtainable, has a stable developmental potential even after prolonged culture, forms derivatives of all three embryonic germ layers from the progeny of a single cell and generates teratomas after injection into immunosuppressed mice (Mason and Dunnill 2008). Stem cell-based therapy has the potential to offer important new treatment options for insulin-dependent diabetes, Parkinson’s disease, cardiovascular, renal, musculoskeletal and retinal diseases and spinal cord diseases and trauma, among others. A critical question in this field is to establish which stem cells could be efficiently used clinically.

In 1981, Martin and Evans achieved a milestone in stem cell biology with the derivation of mouse embryonic stem cells (ESCs; Evans and Kaufman 1981). The subsequent derivation of pluripotent human ESCs in 1998 by James Thomson (Thomson et al. 1998) and pluripotent stem cells from human primordial germ cells (Shamblott et al. 1998) ushered in a revolution in the field of regenerative medicine and tissue engineering. However, the destruction of human embryos to obtain ESCs and the need for therapeutic cloning to use them optimally made their clinical application highly controversial. In addition to ethical, legal and moral issues, ESCs have inherent limitations that must be overcome before their clinical use. One prime concern is the potential tumorigenicity of these cells in vivo. Although efforts to eliminate this possibility are underway, it remains a serious issue (Blum and Benvenisty 2008; Fujikawa et al. 2005; Strulovici et al. 2007; Wu, Boyd, and Wood 2007). Other concerns are immune rejection (Drukker et al. 2002; Wobus and Boheler 2005), genetic instability and incomplete epigenetic reprogramming (Wobus and Boheler 2005). These concerns have
sparked interest within the scientific community in finding alternate sources of pluripotent/multipotent cells that have similar can as ESCs, but potentially circumvent the problems associated with these cells.

The derivation of induced pluripotent stem cells (iPSCs) through the introduction of a small combination of transcription factors into terminally differentiated cells has raised the possibility of producing an alternate pluripotent stem cell source for use in regenerative medicine. Researchers at Kyoto University, Japan, were first to identify conditions that allowed mouse skin fibroblasts to be induced into pluripotency (Takahashi and Yamanaka 2006) and a year later human skin fibroblasts were also induced to pluripotency using this same approach (Takahashi, Okita et al. 2007; Takahashi, Tanabe et al. 2007; Yu et al. 2007). The iPSC technology has immense potential for clinical therapy as these cells avoid some ethical and moral issues associated with ESCs. The technology involves producing critical levels of proteins needed for pluripotency through introducing the genes into the target cells exogenously using viral vectors (Takahashi, Tanabe et al. 2007; Takahashi and Yamanaka 2006; Yu et al. 2007), adenoviral vectors (Stadtfeld et al. 2008; Okita et al. 2008) or non-viral plasmids (Okita et al. 2008) or introducing the actual recombinant proteins themselves into cells (Zhou et al. 2009). Although initially there was concern over use of viral vectors integrating into the human genome and potentially inducing neoplastic changes, the use of alternate methods to deliver the pluripotency genes appears to circumvent that problem. Nonetheless, because there is genetic manipulation involved (Stadtfeld et al. 2010; Stadtfeld and Hochedlinger 2010) and an increased risk of tumorigenicity (Nakagawa et al. 2008; Ben-David and Benvenisty 2011; Kooreman and Wu 2010) extensive research has to be conducted before iPSCs are used clinically. Since iPSCs can be derived from patientspecific cells, one potential benefit of these cells was a low or no risk of immune rejection. However, a recent finding suggests that this might not be true: In contrast to derivatives of ESCs, abnormal gene expression in iPSCs introduced into syngeneic mice in vivo induced T-cell-dependent immune responses, leading to immune infiltration and ultimately rejection of these cells (Zhao et al. 2011). This raises concerns for use of these cells in regenerative medicine. As with any new technology, there are a number of other hurdles to overcome before using iPSCs clinically, such as refractoriness of many adult cells to reprogramming, transient epigenetic memory of donor cells (Kim et al. 2010; Polo et al. 2010) and possible non-recurrent mutations. Despite these concerns, the tremendous progress and obvious potential of iPSCs over the past few years has overshadowed work on other potentially pluripotent stem cells, although some of these cells may ultimately offer therapeutic potential equal to that of iPSCs.

2. Progress in regenerative medicine

In 2010, two ESC-based human clinical trials were approved by the U. S. Food and Drug Administration, one initiated by Geron Corporation and the other by Advanced Cell Technology. Though the clinical trials are underway, there is concern that introducing stem cells that have not transformed into specialized cells into patients may pose the risk of teratoma formation. However, remarkable progress has been made in cell-based regenerative medicine over the past decade. The cell-therapy based industry now has an annual revenue of over a billion dollars and it is projected to rise to $5.1 billion by 2014
Spermatogonial Stem Cells: An Alternate Source of Pluripotent Stem Cells for Regenerative Medicine

(Mason and Manzotti 2010). The initial research and monetary investment to develop stem-cell based therapy is high. However, since the treatment involves transplantation of cells or tissues that can function normally for extended periods of time or even potentially for the remainder of a patient’s life, there is negligible need for ongoing treatment, rendering this modality of treatment potentially cost-effective (Mason and Dunnill 2008).

The limitations and problems associated with iPSCs suggest that they may not offer the optimal solution for all aspects of regenerative medicine, raising the question of whether other stem cells may be preferable in some or potentially all regenerative medicine applications. Other stem cells that have received widespread attention in this regard include hematopoietic (HSC), mesenchymal and fetal cord blood stem cells. An adult allogenic stem cell source with developmental potential similar to ESCs and iPSCs would potentially be the most promising clinical approach if an optimal starting cell was found.

Another stem cell that has been studied extensively for years and has recently been shown to have potential in regenerative medicine is the spermatogonial stem cell (SSC). This chapter focuses on recent developments in this field and the advantages and limitations of SSC use in regenerative medicine. We also briefly discuss other multipotent stem cells that may have significant clinical use.

3. Spermatogonial Stem Cells

In mammalian testes, SSCs are found along the basement membrane of seminiferous tubules. They produce the spermatogenic lineage, ensuring lifelong fertility of the individual. Like other stem cells, SSCs are undifferentiated and capable of self-renewal. While in the testicular microenvironment, they differentiate only into one specialized cell lineage, spermatozoa. However, when SSCs are isolated from the testis and placed into a different environment, they acquire or manifest pluripotency and differentiate into tissues belonging to all three embryonic germ layers (Kanatsu-Shinohara et al. 2008; Golestaneh et al. 2009; Simon et al. 2009; Ning et al. 2010). This property makes SSCs a powerful potential source of cells for regenerative therapy.

3.1 Development and differentiation potential of SSCs

In the embryo, the germ line arises from primordial germ cells (PGCs). PGCs are initially identifiable as a small cluster of cells in the proximal epiblast near the extra-embryonic ectoderm. This lineage differentiates under the influence of bone morphogenetic proteins (BMPs) and diverges from the somatic lineage in the late embryonic and early fetal stage (Lawson et al. 1999; Ying et al. 2000). Due to their extra-embryonal origin, they are not classified as belonging to a particular embryonic germ layer. Therefore, they are not subjected to many of the differentiation signals other stem cells receive (Lawson and Hage 1994; Simon, Hess, and Cooke 2010); this may allow them to remain more undifferentiated than other stem cells. Following their initial development, PGCs subsequently migrate into the mesoderm, the endoderm (hindgut) and across the dorsal mesentery to reach the developing gonads at about 4-5 weeks of gestation in humans and 11-13 day post-coitum in rodents (Culty 2009). In the testis, PGCs then become mitotically quiescent until birth, and are called gonocytes. Shortly after birth, gonocytes resume mitosis and migrate to the basement membrane of seminiferous tubules, where they form SSCs and remain...
throughout life. Thus, the embryological origin of SSCs is unique. This may facilitate their potential for differentiation into cell types of different germ cell layers and underlines their clinical potential for regenerative medicine. Furthermore, teratomas occur exclusively in gonads (Stevens 1964) and are of germ cell origin, and gene expression in early germ cells is very similar to ESCs (Zwaka and Thomson 2005; Simon, Hess, and Cooke 2010), which emphasizes the broad developmental potential of SSCs. SSCs express genes such as POU domain class 5, transcription factor 1 (Pou5f1; Huang et al. 2009; Bhartiya et al.), Lin 28 (Zheng et al. 2009), undifferentiated embryonic cell transcription factor 1 (UTF-1) and Zinc finger protein 42 (Rex-1; Kristensen et al. 2008), which impart pluripotency. However, expression of another pluripotency gene, Nanog, is repressed in the testis by transformation related protein 53 (TRP53) and phosphatase and tensin homolog (PTEN). Both proteins belong to a critical signaling pathway preventing SSCs from being pluripotent while in the testis (Kuijk et al. 2009). Overall, this gene expression pattern suggests that SSCs have a gene profile similar to ESCs and thus are more undifferentiated than other adult stem cells.

3.2 Current methods of isolation and propagation of SSCs with emphasis on human SSC isolation

Spermatogonial stem cell constitute only 0.03% of the total germ cell population in rodent and human testis (Tegelenbosch and de Rooij 1993). Thus, their small numbers and the lack of specific markers are the main hurdles to their characterization. Nonetheless, significant progress has recently been made in the isolation and propagation of cells with SSCs properties from rodent (Dym et al. 2009; Guan et al. 2009; Kanatsu-Shinohara, Takehashi, and Shinohara 2008; Kubota, Avarbock, and Brinster 2004; Oatley and Brinster 2006, 2008; Ogawa et al. 2003; Hofmann et al. 2005; Kanatsu-Shinohara et al. 2010) and human testes (Conrad et al. 2008; Glaser et al. 2008; Golestaneh et al. 2009; Kossack et al. 2009; Zovoilis et al. 2008; Izadyar et al. 2011; He et al. 2009). Human testicular tissue is currently obtained from testicular biopsies (Izadyar et al. 2011; Kossack et al. 2009), orchietomies (Izadyar et al. 2011) and organ donors (Golestaneh et al. 2009). Testicular biopsies of approximately one gram can yield sufficient number of human SSCs for most clinical applications. Although our knowledge of mouse and human SSCs phenotype is still limited, studies suggest that human SSCs express proteins such as cluster of differentiation antigens 49f, 90 and 133 (CD49f, CD90, and CD133, respectively), glial cell line-derived neurotrophic factor family receptor alpha 1 (GFRA1), G protein-coupled receptor 125 (GPR125), melanoma antigen family A 4 (MAGE4), promyelocytic leukemia zinc finger (PLZF) and stage-specific embryonic antigen-4 (SSEA-4; Costoya et al. 2004; Conrad et al. 2008; He et al. 2009; Izadyar et al. 2011). Using these markers in magnetic- or fluorescent-activated cell sorting, SSCs can be isolated with a high degree of purity (Gassei et al. 2009; Izadyar et al. 2011; Kokkinaki et al. 2009; Simon et al. 2010). Although there have been no definitive culture conditions for propagation of either mouse or human SSCs, culture systems established by different groups seem to be conducive for their propagation. At least in rodents, glial cell line-derived neurotrophic factor (GDNF) was found to be essential to maintain SSCs in an undifferentiated state in vivo and in vitro (Tyagi et al. 2009; Hofmann 2008; Sariola and Immonen 2008; Oatley, Avarbock, and Brinster 2007; Oatley et al. 2006; Naughton et al. 2006; Kubota, Avarbock, and Brinster 2004; Meng et al. 2000).
3.3 Spermatogonial stem cells are pluripotent

In the testicular microenvironment, SSCs produce only the spermatogenic lineage, and the assumption was that this was their sole potential developmental fate. However, the iconoclastic finding of Kanatsu-Shinohara et al. (Kanatsu-Shinohara et al. 2004) demonstrated that neonatal murine SSCs produced ESC-like cells when isolated from the testis and grown for extended periods in ESC culture conditions. Although initial work was done with neonatal SSCs (Kanatsu-Shinohara et al. 2004; Kanatsu-Shinohara et al. 2008; Simon et al. 2009), subsequent work showed that adult murine SSCs (Glaser et al. 2008; Izadyar et al. 2008; Seandel et al. 2007; Guan et al. 2006) grown for 4-7 weeks in vitro also produced a low frequency of ESC-like colonies. These ESC-like cells can give rise to cell types derived from all three embryonic germ layers, and also produce teratomas when injected subcutaneously into nude mice. In addition, these ESC-like cells contribute to embryonic development when injected into blastocysts. ESC-like cells derived from SSCs have been termed multipotent germline stem cells (mGSCs) and these cells have been differentiated into many cell types. For example, two separate groups demonstrated that mGSCs could differentiate into mature cardiac and endothelial cells and that these cardiac cells were contractile and had electric potentials and ion channels (Baba et al. 2007; Guan et al. 2007). mGSCs derived from adult mouse SSCs could be differentiated into functional neurons and glia (Glaser et al. 2008; Streckfuss-Bomeke et al. 2009). Pluripotent stem cells were derived from adult mGSCs that not only could differentiate into a variety of cell types both in vivo and in vitro, but also showed germline transmission to the next generation when injected into blastocysts (Ko et al. 2009). Moreover, mGSCs have pluripotency characteristics similar to ESCs such as telomerase activity, telomere length and hypomethylation of pluripotency marker genes (Zechner et al. 2009).

In recent years, several research groups reported methodologies for isolation and culture of human SSCs and also demonstrated that these cells were pluripotent/multipotent (Conrad et al. 2008; Golestaneh et al. 2009; Kossack et al. 2009; Dym et al. 2009; Izadyar et al. 2011). SSCs isolated from human testicular tissues and cultured for a week or more spontaneously produced ESC-like small colonies, which were then transferred into ESC media and cultured for about 4 weeks to get sufficient numbers of ESC-like colonies and these ESC-like cells could then be differentiated into specific cell types. These results indicate that human SSCs have the potential to be used as an alternate source of pluripotent stem cells in regenerative cell therapy, without the ethical concerns of ESC and the concerns involving exogenous gene introduction in iPSCs.

4. Direct differentiation of spermatogonial stem cells

4.1 Epithelial-mesenchymal interactions

Epithelial-mesenchymal interactions are critical for organogenesis in many organs such as lung, prostate, mammary gland, liver, pancreas and salivary glands (Grobstein 1953). Mesenchyme, which is undifferentiated connective tissue, signals to the epithelium to induce epithelial morphogenesis and cytodifferentiation in a wide variety of organs. The central role of epithelial-mesenchymal interactions in organ development was postulated initially by Pander and later experimentally demonstrated by Spemann and Saunders (in Simon, Hess, and Cooke 2010).
Classical tissue recombination experiments conducted by Cunha and coworkers with reproductive tissue demonstrated that the mesenchyme dictates the fate of the epithelium in various reproductive tissues. The urogenital sinus is an ambisexual fetal organ that gives rise to the prostate in males and a portion of the vagina in females. Under the influence of androgen, urogenital sinus mesenchyme (UGM) induces urogenital sinus epithelium (UGE) to differentiate into prostatic epithelium and UGM also regulates epithelial ductal morphogenesis and cytodifferentiation in prostate. UGM also instructively induces prostatic morphogenesis in other epithelia (Cunha et al. 1983; Cunha, Lung, and Reese 1980; Cunha, Sekkingstad, and Meloy 1983). For example, UGM instructively induces adult bladder epithelium to form prostatic epithelium in tissue recombinants in vivo (Cunha et al. 1983). Similarly, neonatal uterine mesenchyme instructively induces neonatal vaginal epithelium to form uterine epithelium (Cunha 1976).

4.1.1 Potential signaling pathways involved in epithelial-mesenchymal interactions

Although mesenchymal paracrine signaling is essential for determining epithelial fate, the specific signaling pathway(s) involved in this phenomenon remain unclear. Some possible signaling molecules are Wnt7a (Miller and Sassoon 1998), hepatocyte growth factor (HGF) and fibroblast growth factor (FGF) family molecule(s) in the uterus (Chen, Spencer, and Bazer 2000, 2000), HGF and FGF family molecule(s) for lung organogenesis (Ohmichi et al. 1998) (for review see Kumar et al. 2005,) and FGF and Wnt and Hedgehog signaling in the prostate (for review see Thomson, Cunha, and Marker 2008; Cunha, Cooke, and Kurita 2004; Lin and Wang, 2010; Taylor et al. 2009).

4.1.2 Mesenchyme dictates the fate of stem cell differentiation

The demonstrations that epithelial-mesenchymal interactions are essential for organogenesis also triggered interest in using this approach in regenerative therapy. ESCs were differentiated into prostatic epithelium by recombining mouse UGM and human ESCs and growing these tissue recombinations in vivo (Taylor et al. 2006). Using a similar methodology (Oottamasathien et al. 2007; Anumathan et al. 2008), human ESCs or bone marrow-derived mesenchymal stem cells have been differentiated into bladder epithelium by exposing these cells to the inductive influence of bladder mesenchyme in a tissue recombinant. More recently, Taylor et al. demonstrated that stroma could induce adult stem cells to express dual phenotypes (Taylor et al. 2009). Prostatic stroma induced putative mammary epithelial stem cells to generate glandular epithelia expressing both prostatic and mammary markers. These results demonstrate that the mesenchyme can instructively direct the differentiation of ESCs or other stem cells into a specific cell fate.

4.2 Spermatogonial stem cells differentiate into tissues of all three embryonic germ layers in response to instructive inducers

Based on demonstrations of the importance of the stem cell niche (Tyagi et al. 2009; de Rooij 2009; Hess et al. 2006; Simon et al. 2010; Oatley, Racicot, and Oatley 2010), the pluripotential nature of SSCs and the instructive potential of various mesenchymes, we postulated and subsequently demonstrated that neonatal mouse SSCs could directly differentiate into prostatic, uterine and skin epithelium (Simon et al. 2009) when recombined with the
appropriate mesenchyme and grafted in vivo (Fig. 1). To track cell lineages derived from SSCs in tissue recombinations and verify that these cells were undergoing differentiation, wt transgenic C57BL/6 mice expressing enhanced green fluorescent protein (GFP) ubiquitously were used. For example, UGM derived from wild-type mice (wt-UGM) were recombined with SSCs derived from mice expressing GFP (G-SSC) and grafted under the renal capsule of syngeneic male hosts. After 4 weeks of growth, the epithelium in these, wt-UGM + G-SSC, tissue recombinants expressed NKX3.1, a prostatic epithelial marker and androgen receptor but not germ cell nuclear antigen 1 (GCNA1), a germ cell marker. The tissue recombinants had an epithelium that stained intensely for GFP (Fig. 1A), indicating that it was of SSC origin, while stromal cells lacked GFP staining. Similarly uterine mesenchyme (UtM) from mice expressing GFP (G-UtM) recombined with SSCs derived from wt-mice (wt-SSC) differentiated into uterine epithelium that expressed cytokeratin 8 (CK8), estrogen receptor-alpha and progesterone receptor. In these G-UtM + wt-SSC tissue recombinants, stromal cells strongly expressed GFP, while epithelium did not, indicating that the epithelium was of SSC origin (Fig. 1B). This approach provides a method to directly differentiate SSCs into specific cell types from all three embryonic germ layers without the extended culture period needed in vitro to produce ESC-like cells that can subsequently differentiate into various derivatives.

Fig. 1. Differentiation of SSCs into prostatic and uterine epithelium. A) Urogenital sinus mesenchyme (UGM) from wild-type (wt) mice was recombined with SSCs derived from mice that expressed enhanced green fluorescent protein (G) ubiquitously and was grafted under the renal capsule of syngeneic male hosts. After 4 weeks of in vivo growth, the wt-UGM + G-SSC tissue recombinants formed prostatic epithelium (E) that was of SSC origin expressing GFP and androgen receptor (AR, red nuclei). B) Uterine mesenchyme (UtM) from GFP mice was recombined with SSCs derived from wt mice and grafted under the renal capsule of syngeneic female hosts. After 4 weeks of growth, the G-UtM + wt-SSC tissue recombinants formed uterine epithelium (E) that was of SSC origin expressing cytokeratin 8 (CK8). Stromal cells (S) express GFP but E does not. SSCs do not express AR or CK8.

When SSCs were mixed with mammary epithelial cells and grafted into the mammary fat pad in vivo, SSCs differentiated into mammary epithelial cells, but the stem cells alone could not be differentiated into mammary cells (Boulanger et al. 2007). This suggests that the
inductive potential of the adult mammary fat pad might not be sufficient for directing the differentiation of SSCs into mammary epithelial cells. This is a potential hurdle for the use of this methodology, as the inductive mesenchyme for most of the organs is present during fetal life, and as they transition to form adult stromal cells they might lose this ability to instructively induce other epithelia. However, a recent study demonstrated direct differentiation of SSCs into hematopoietic cells (Ning et al., 2010). When SSCs were injected into the bone marrow of adult female mice, these mice had Y chromosome positive-cells that had phenotypical and functional characteristics of hematopoietic cells both in vivo and in vitro, emphasizing both the pluripotential nature of SSCs and that the microenvironment even in adult organs plays a decisive role in directing the differentiation of SSCs.

As discussed earlier, our understanding of the mechanistic basis of epithelial-mesenchymal interactions is fragmentary. Fetal mesenchymes are potent instructive inducers, and one of the challenges for using this methodology will be to determine whether or not adult stroma is capable of similar instructive inductions. Once we are able to dissect out the molecular mechanisms used by mesenchyme to instructively induce epithelial morphogenesis, it will be feasible to expose SSCs to the inductive signals produced by these tissues in vitro, on artificial scaffolds or some other arrangement. Another major limitation of this methodology is that it is inapplicable to tissues that do not involve epithelial-mesenchymal interactions during development. However, the direct differentiation of SSCs into hematopoietic cells (Ning et al., 2010) discussed above suggests that SSCs will differentiate into a specific tissue type when exposed to an appropriate microenvironment, even in the absence of epithelial-mesenchymal interactions. Thus further research is necessary to determine both the full developmental potential of SSCs and the most appropriate methodology for inducing specific cell types, but SSCs appear to have great potential in this regard.

4.3 Mechanism of differentiation of spermatogonial stem cells into other cell types

The mechanism of differentiation of SSCs into other cell types under the influence of instructive inducers is poorly understood. One possibility is that in response to an inductive mesenchyme, the SSCs de-differentiate into ESC-like cells (as has been reported in vitro), and then subsequently differentiate into a new epithelia. However, our preliminary studies indicate that SSCs may not undergo a de-differentiation step in the presence of an inductive mesenchyme, but instead may differentiate directly from SSCs to another epithelial type without going through an intermediate ESC-like cell stage. Shinohara and coworkers (Kanatsu-Shinohara et al. 2008) demonstrated that a single spermatogonial stem cell could produce an embryonic stem-like line that was multipotent and germline stem cells that were committed to spermatogenesis, indicating that all SSCs may be capable of becoming pluripotent. This is supported by other studies (Ko et al. 2009). Conversely, Izadyar et al. suggested that there are two distinct populations of SSCs, one that is OCT4+ and c-KIT- that gives rise to multipotent cells and another that is OCT4+ and c-KIT+ that gives rise to the spermatogenic lineage (Izadyar et al. 2008). A definitive elucidation of how SSCs differentiate into other tissue types, as well as definitively establishing whether all SSCs or a specific subpopulation can be converted into other tissues, will be an essential prerequisite for successful use of this approach in a clinical setting. Nonetheless, SSCs can be differentiated into specific cell types using different approaches and be a potential source for pluripotent cells for stem cell-based therapy (Fig. 2).
Fig. 2. Potential use of spermatogonial stem cells (SSCs) in regenerative medicine. Spermatogonia in the murine seminiferous tubule expressing PLZF, a SSC marker. SSCs are isolated from the testis using magnetic- or fluorescent-activated cell sorting. Some of the possible methods of differentiating SSCs into specific cell types are 1) Long-term culture of SSCs, selection for cells that form embryonic stem cell-like colonies and subsequent culture and differentiation of these pluripotent cells into specific cell types. 2) Recombination of SSCs with instructive inducers to directly differentiate SSCs into specific epithelial cell types; 3) Direct injection to a specific site of injury or specific microenvironment. Since SSCs are unspecialized, they could home and respond to signals in the new microenvironment and differentiate into cells of all three embryonic germ layers.

5. Advantages and limitations of SSCs over other pluripotent stem cell sources

SSCs, as well as other adult derived stem cells, may be safer to use therapeutically than ESCs or iPSCs. Since SSCs are more differentiated than ESCs, they are less likely to induce teratomas (Kossack et al. 2009). However, the risk of malignant transformation cannot be totally rejected since SSCs are relatively more undifferentiated than other adult stem cells. This type of problem is illustrated by the formation of brain tumors from donor-derived cells in patients who received fetal stem cells for treatment of ataxia-telangiectasia (Amariglio et al. 2009), emphasizing that tumorigenicity is the biggest impediment for the use of pluripotent stem cells in cell therapy. Another obstacle is the immunogenicity of SSCs and potential risk of rejection of the cells (Dressel et al. 2009). But immune rejection of autologous or allogenic stem cell transplants can be minimized by routine immunosuppression treatments as is used for organ transplantation. Another possible alternative is genetic manipulation of stem cells and elimination of genes responsible for immune rejection (Wobus and Boheler 2005).
6. Alternate sources of stem cells for use in regenerative medicine

The use of stem cells in regenerative medicine began when bone marrow cells were transplanted to treat acute leukemia (Thomas et al. 1959), and presently HSC therapy is the only stem cell therapy widely used clinically (Helmy et al. 2010). There is growing evidence that HSCs are plastic—and can give rise to tissues other than those of the blood system, e.g., liver cells (Lagasse et al. 2000). Another readily available source is mesenchymal stem cells that can be isolated from adult tissue, fetal tissue and umbilical cord blood. These cells can differentiate into osteoblasts, chondrocytes and adipocytes (Friedenstein et al. 1974; Pittenger et al. 1999) neurons (Cho et al. 2005), astrocytes (Kopen, Prockop, and Phinney 1999) and hepatocyte-like cells (Petersen et al. 1999). The use of adipose stem cells as a source for cell therapy is increasing rapidly as methods of isolation and culture are standardized; subcutaneous depots are easily accessible, replenishable and are often abundant. Adult stem cells derived from adipose tissues can differentiate in vitro into many cell types including adipocyte, chondrocyte, endothelial, epithelial, hematopoietic support, hepatocyte, neuronal, myogenic, and osteoblast lineages (Gimble and Guilak 2003; Halvorsen et al. 2001; Safford et al. 2002; Zuk et al. 2001). Fetal stem cells are self-renewing cells located in various types of fetal tissue, including umbilical cord blood, umbilical cord matrix, fetal blood and the amniotic membrane (Reinisch and Strunk 2009; Jager et al. 2009; Zeddou et al., 2010). Umbilical cord blood contain multiple populations of stem cells that can be effective in treating many diseases such as hematological malignancies, hemoglobinopathies, metabolic disorders and the greatest advantage of these cells is decreased immune rejection (Liao et al., 2011).

| Stem Cells                          | Advantages                                      | Major limitations |
|------------------------------------|-------------------------------------------------|-------------------|
| Embryonic stem cells               | Pluripotent                                     | Ethical concerns  |
|                                    | Indefinite self-renewal potential               | Tumorigenicity    |
|                                    |                                                  | Therapeutic cloning |
|                                    |                                                  | involved           |
| Induced pluripotent cells          | Pluripotent                                     | Introduction of exogenous genes |
|                                    | Initial source of cells are easy to obtain      | Tumorigenicity    |
|                                    | No ethical or moral concerns                    | Genetic instability|
|                                    | Indefinite self-renewal potential               | Use of viral vectors |
|                                    |                                                  | to introduce genes |
| Spermatogonial stem cells          | Pluripotent                                     | Relatively small numbers |
|                                    | No ethical or moral concerns                    | Difficult to maintain in cultures |
| Fetal stem cells (Fetal cord blood, umbilical cord tissue) | Relatively easy to obtain                       | Restricted differentiation |
|                                    | Minimal immunorejection during autologous       | and self-renewal potential |
|                                    | transplantation                                  |                   |
| Adult stem cells (hematopoietic, mesenchymal, adipose) | Easy to obtain                                  | Restricted differentiation |
|                                    | Reduced risk of tumorigenicity                  | and self-renewal potential |

Table 1. Potential advantages and limitations of stem cells in regenerative medicine
7. Conclusions

Among pluripotent/multipotent stem cells (Table 1), spermatogonial stem cells have great potential and some unique advantages. Despite their promise, numerous hurdles must be overcome before clinical use of SSCs. The small population of SSCs in the testis and the difficulty in propagating and maintaining them in culture is one major hurdle. The methodology proposed here is promising but extensive work is needed before its application in regenerative medicine.

8. References

Amariglio, N., A. Hirshberg, B. W. Scheithauer, Y. Cohen, R. Loewenthal, L. Trakhtenbrot, N. Paz, M. Koren-Michowitz, D. Waldman, L. Leider-Trejo, A. Toren, S. Constantini, and G. Rechavi. 2009. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6 (2):e1000029.

Anumanthan, G., J. H. Makari, L. Honea, J. C. Thomas, M. L. Wills, N. A. Bhowmick, M. C. Adams, S. W. Hayward, R. J. Matusik, J. W. Brock, and J. C. Pope. 2008. Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. J Urol 180 (4 Suppl):1778-83.

Baba, S., T. Heike, K. Umeda, T. Iwasa, S. Kaichi, Y. Hiraumi, H. Doi, M. Yoshimoto, M. Kanatsu-Shinohara, T. Shinohara, and T. Nakahata. 2007. Generation of cardiac and endothelial cells from neonatal mouse testis-derived multipotent germline stem cells. Stem Cells 25 (6):1375-83.

Ben-David, U., and N. Benvenisty. 2011. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11 (4):268-77.

Bhartiya, D., S. Kasiviswanathan, S. K. Unni, P. Pethe, J. V. Dhabalia, S. Patwardhan, and H. B. Tongaonkar 2010. Newer insights into premeiotic development of germ cells in adult human testis using Oct-4 as a stem cell marker. J Histochem Cytochem 58 (12):1093-106.

Blum, B., and N. Benvenisty. 2008. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 100:133-58.

Boulanger, C. A., D. L. Mack, B. W. Booth, and G. H. Smith. 2007. Interaction with the mammary microenvironment redirects spermatogenic cell fate in vivo. Proc Natl Acad Sci U S A 104 (10):3871-6.

Chen, C., T. E. Spencer, and F. W. Bazer. 2000. Expression of hepatocyte growth factor and its receptor c-met in the ovine uterus. Biol Reprod 62 (6):1844-50.

Chen, C., T. E. Spencer, and F. W. Bazer. 2000. Fibroblast growth factor-10: a stromal mediator of epithelial function in the ovine uterus. Biol Reprod 63 (3):959-66.

Cho, K. J., K. A. Trzaska, S. J. Greco, J. McArdle, F. S. Wang, J. H. Ye, and P. Rameshwar. 2005. Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells 23 (3):383-91.

Conrad, S., M. Renninger, J. Hennenlotter, T. Wiesner, L. Just, M. Bonin, W. Aicher, H. J. Buhring, U. Mattheus, A. Mack, H. J. Wagner, S. Minger, M. Matzkies, M. Reppel, J. Hescheler, K. D. Sievert, A. Stenzl, and T. Skutella. 2008. Generation of pluripotent stem cells from adult human testis. Nature 456 (7220):344-9.
Costoya, J. A., R. M. Hobbs, M. Barna, G. Cattoretti, K. Manova, M. Sukhwani, K. E. Orwig, D. J. Wolgemuth, and P. P. Pandolfi. 2004. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 36 (6):653-9.

Culty, M. 2009. Gonocytes, the forgotten cells of the germ cell lineage. Birth Defects Res C Embryo Today 87 (1):1-26.

Cunha, G. R. 1976. Stromal induction and specification of morphogenesis and cytodifferentiation of the epithelia of the Mullerian ducts and urogenital sinus during development of the uterus and vagina in mice. J Exp Zool 196 (3):361-70.

Cunha, G. R., P. S. Cooke, and T. Kurita. 2004. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67 (5):417-34.

Cunha, G. R., H. Fuji, B. L. Neubauer, J. M. Shannon, L. Sawyer, and B. A. Reese. 1983. Epithelial-mesenchymal interactions in prostatic development. I. morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 96 (6):1662-70.

Cunha, G. R., B. Lung, and B. Reese. 1980. Glandular epithelial induction by embryonic mesenchyme in adult bladder epithelium of BALB/c mice. Invest Urol 17 (4):302-4.

Cunha, G. R., M. Sekkingstad, and B. A. Meloy. 1983. Heterospecific induction of prostatic development in tissue recombinants prepared with mouse, rat, rabbit and human tissues. Differentiation 24 (2):174-80.

de Rooij, D. G. 2009. The spermatogonial stem cell niche. Microsc Res Tech 72 (8):580-5.

Dressel, R., K. Guan, J. Nolte, L. Elsner, S. Monecke, K. Nayernia, G. Hasenfuss, and W. Engel. 2009. Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by cytotoxic T lymphocytes despite low expression of major histocompatibility complex class I molecules. Biol Direct 4 (1):31.

Drukker, M., G. Katz, A. Urbach, M. Schuldiner, G. Markel, J. Itskovitz-Eldor, B. Reubinoff, O. Mandelboim, and N. Benvenisty. 2002. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 99 (15):9864-9.

Dym, M., Z. He, J. Jiang, D. Pant, and M. Kokkinaki. 2009. Spermatogonial stem cells: unlimited potential. Reprod Fertil Dev 21 (1):15-21.

Evans, M. J., and M. H. Kaufman. 1981. Establishment in culture of pluripotent cells from mouse embryos. Nature 292 (5819):154-6.

Friedenstein, A. J., R. K. Chailakhyan, N. V. Latsinik, A. F. Panasyuk, and I. V. Keiliss-Borok. 1974. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17 (4):331-40.

Fujikawa, T., S. H. Oh, L. Pi, H. M. Hatch, T. Shupe, and B. E. Petersen. 2005. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol 166 (6):1781-91.

Gassei, K., J. Ehmcke, R. Dhir, and S. Schlatt. 2009. Magnetic activated cell sorting allows isolation of spermatogonia from adult primate testes and reveals distinct GFRα1-positive subpopulations in men. J Med Primatol 39 (2):83-91.

Gimble, J. M., and F. Guilak. 2003. Differentiation potential of adipose derived adult stem (ADAS) cells. Curr Top Dev Biol 58:137-60.
Glasier, T., T. Opitz, T. Kischlat, R. Konang, P. Sasse, B. K. Fleischmann, W. Engel, K. Nayernia, and O. Brustle. 2008. Adult germ line stem cells as a source of functional neurons and glia. Stem Cells 26 (9):2434-43.

Golestaneh, N., M. Kokkinaki, D. Pant, J. Jiang, D. DeStefano, C. Fernandez-Bueno, J. D. Rone, B. R. Haddad, G. I. Gallicano, and M. Dym. 2009. Pluripotent stem cells derived from adult human testes. Stem Cells Dev 18 (8):1115-26.

Grobstein, C. 1953. Inductive epitheliomencesenchymal interaction in cultured organ rudiments of the mouse. Science 118 (3054):52-5.

Guan, K., K. Nayernia, L. S. Maier, S. Wagner, R. Dressel, J. H. Lee, J. Nolte, F. Wolf, M. Li, W. Engel, and G. Hasenfuss. 2006. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 440 (7088):1199-203.

Guan, K., S. Wagner, B. Unsold, L. S. Maier, D. Kaiser, B. Hemmerlein, K. Nayernia, W. Engel, and G. Hasenfuss. 2007. Generation of functional cardiomyocytes from adult mouse spermatogonial stem cells. Circ Res 100 (11):1615-25.

Guan, K., F. Wolf, A. Becker, W. Engel, K. Nayernia, and G. Hasenfuss. 2009. Isolation and cultivation of stem cells from adult mouse testes. Nat Protoc 4 (2):143-54.

Halvorsen, Y. D., D. Franklin, A. L. Bond, D. C. Hitt, C. Auchter, A. L. Boskey, E. P. Paschalikis, W. O. Wilkison, and J. M. Gimble. 2001. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. Tissue Eng 7 (6):729-41.

He, Z., M. Kokkinaki, J. Jiang, I. Dobrinkski, and M. Dym. 2009. Isolation, characterization, and culture of human spermatogonia. Biol Reprod 82 (2):363-72.

Helmy, K. Y., S. A. Patel, K. Silverio, L. Pliner, and P. Rameshwar. 2010. Stem cells and regenerative medicine: accomplishments to date and future promise. Ther Deliv 1 (5):693-705.

Hess, R. A., P. S. Cooke, M. C. Hofmann, and K. M. Murphy. 2006. Mechanistic insights into the regulation of the spermatogonial stem cell niche. Cell Cycle 5 (11):1164-70.

Hofmann, M. C. 2008. Gdnf signaling pathways within the mammalian spermatogonial stem cell niche. Mol Cell Endocrinol 288 (1-2):95-103.

Hofmann, M.C., L. Braydich-Stolle, and M. Dym. 2005. Isolation of male germ-line stem cells; influence of GDNF. Dev Biol 279 (1):114-124.

Huang, Y. H., C. C. Chin, H. N. Ho, C. K. Chou, C. N. Shen, H. C. Kuo, T. J. Wu, Y. C. Wu, Y. C. Hung, C. C. Chang, and T. Y. Ling. 2009. Pluripotency of mouse spermatogonial stem cells maintained by IGF-1-dependent pathway. FASEB J 23 (7):2076-87.

Izadyar, F., F. Pau, J. Marh, N. Slepko, T. Wang, R. Gonzalez, T. Ramos, K. Howerton, C. Sayre, and F. Silva. 2008. Generation of multipotent cell lines from a distinct population of male germ line stem cells. Reproduction 135 (6):771-84.

Izadyar, F., J. Wong, C. Maki, J. Pacchiarotti, T. Ramos, K. Howerton, C. Yuen, S. Greilach, H. H. Zhao, M. Chow, Y. C. Chow, J. Rao, J. Barritt, N. Bar-Chama, and A. Copperman. 2011. Identification and characterization of repopulating spermatogonial stem cells from the adult human testis. Hum Reprod 26 (6):1296-306.

Jager, M., C. Zilkens, B. Bittersohl, and R. Krauspe. 2009. Cord blood--an alternative source for bone regeneration. Stem Cell Rev 5 (3):266-77.

Kanatsu-Shinohara, M., K. Inoue, J. Lee, M. Yoshimoto, N. Ogonuki, H. Miki, S. Baba, T. Kato, Y. Kazuki, S. Toyokuni, M. Toyoshima, O. Niwa, M. Oshimura, T. Heike, T.
Nakahata, F. Ishino, A. Ogura, and T. Shinohara. 2004. Generation of pluripotent stem cells from neonatal mouse testis. Cell 119 (7):1001-12.

Kanatsu-Shinohara, M., K. Inoue, N. Ogonuki, H. Morimoto, A. Ogura, and T. Shinohara. 2010. Serum- and feeder-free culture of mouse germline stem cells. Biol Reprod 84 (1):97-105.

Kanatsu-Shinohara, M., J. Lee, K. Inoue, N. Ogonuki, H. Miki, S. Toyokuni, M. Ikawa, T. Nakamura, A. Ogura, and T. Shinohara. 2008. Pluripotency of a single spermatogonial stem cell in mice. Biol Reprod 78 (4):681-7.

Kanatsu-Shinohara, M., M. Takehashi, and T. Shinohara. 2008. Brief history, pitfalls, and prospects of mammalian spermatogonial stem cell research. Cold Spring Harb Symp Quant Biol 73:17-23.

Kim, K., A. Doi, B. Wen, K. Ng, R. Zhao, P. Cahan, J. Kim, M. J. Aryee, H. Ji, L. I. Ehrlich, A. Yabuuchi, A. Takeuchi, K. C. Cunniff, H. Hongguang, S. McKinney-Freeman, O. Naveiras, T. J. Yoon, R. A. Irizarry, N. Jung, J. Seita, J. Hanna, P. Murakami, R. Jaenisch, R. Weissleder, S. H. Orkin, A. P. Feinberg, and G. Q. Daley. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 467 (7313):285-90.

Ko, K., N. Tapia, G. Wu, J. B. Kim, M. J. Bravo, P. Sasse, T. Glaser, D. Ruau, D. W. Han, B. Greber, K. Hausdorfer, V. Sebastian, M. Stehling, B. K. Fleischmann, O. Brustle, M. Zenke, and H. R. Scholer. 2009. Induction of pluripotency in adult unipotent germline stem cells. Cell Stem Cell 5 (1):87-96.

Kokkinaki, M., T. L. Lee, Z. He, J. Jiang, N. Golestaneh, M. C. Hofmann, W. Y. Chan, and M. Dym. 2009. The molecular signature of spermatogonial stem/progenitor cells in the 6-day-old mouse testis. Biol Reprod 80 (4):707-17.

Kooreman, N. G., and J. C. Wu. 2010. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J R Soc Interface 7 Suppl 6:S753-63.

Kopen, G. C., D. J. Prokop, and D. G. Phinney. 1999. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 96 (19):10711-6.

Kossack, N., J. Meneses, S. Shefi, H. N. Nguyen, S. Chavez, C. Nicholas, J. Gromoll, P. J. Turek, and R. A. Reijo-Pera. 2009. Isolation and characterization of pluripotent human spermatogonial stem cell-derived cells. Stem Cells 27 (1):138-49.

Kristensen, D. M., J. E. Nielsen, N. E. Skakkebaek, N. Graem, G. K. Jacobsen, E. Rajpert-De Meyts, and H. Leffers. 2008. Presumed pluripotency markers UTF-1 and REX-1 are expressed in human adult testes and germ cell neoplasms. Hum Reprod 23 (4):775-82.

Kubota, H., M. R. Avarbock, and R. L. Brinster. 2004. Growth factors essential for self-renewal and expansion of mouse spermatogonial stem cells. Proc Natl Acad Sci U S A 101 (47):16489-94.

Kuijk, E. W., A. van Mil, B. Brinkhof, L. C. Penning, B. Colenbrander, and B. A. Roelen. 2009. PTEN and TRP53 independently suppress Nanog expression in spermatogonial stem cells. Stem Cells Dev 19 (7):979-88.

Kumar, V. H., S. Lakshminrusimha, M. T. El Abiad, P. R. Chess, and R. M. Ryan. 2005. Growth factors in lung development. Adv Clin Chem 40:261-316.
Spermatogonial Stem Cells: An Alternate Source of Pluripotent Stem Cells for Regenerative Medicine

Lagasse, E., H. Connors, M. Al-Dhalimy, M. Reitsma, M. Dohse, L. Osborne, X. Wang, M. Finegold, I. L. Weissman, and M. Grompe. 2000. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6 (11):1229-34.

Lawson, K. A., N. R. Dunn, B. A. Roelen, L. M. Zeinstra, A. M. Davis, C. V. Wright, J. P. Korving, and B. L. Hogan. 1999. Bmp4 is required for the generation of primordial germ cells in the mouse embryo. Genes Dev 13 (4):424-36.

Lawson, K. A., and W. J. Hage. 1994. Clonal analysis of the origin of primordial germ cells in the mouse. Ciba Found Symp 182:68-84; discussion 84-91.

Liao, Y., M. B. Geyer, A. J. Yang, and M. S. Cairo. 2011. Cord blood transplantation and stem cell regenerative potential. Exp Hematol 39 (4):393-412.

Lin, Y., and F. Wang 2010. FGF signalling in prostate development, tissue homoeostasis and tumorigenesis. Biosci Rep 30 (5):285-91.

Mason, C., and P. Dunnill. 2008. A brief definition of regenerative medicine. Regen Med 3 (1):1-5.

Mason, C., and P. Dunnill. 2008. The strong financial case for regenerative medicine and the regen industry. Regen Med 3 (3):351-63.

Mason, C., and E. Manzotti. 2010. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen Med 5 (3):307-13.

Meng, X., M. Lindahl, M. E. Hyvonen, M. Parvinen, D. G. de Rooij, M. W. Hess, A. Raatikainen-Ahokas, K. Sainio, H. Rauvala, M. Lakso, J. G. Pichel, H. Westphal, M. Saarma, and H. Sariola. 2000. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 287 (5457):1489-93.

Miller, C., and D. A. Sassoon. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125 (16):3201-11.

Nakagawa, M., M. Koyanagi, K. Tanabe, K. Takahashi, T. Ichisaka, T. Aoi, K. Okita, Y. Mochiduki, N. Takizawa, and S. Yamanaka. 2008. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26 (1):101-6.

Naughton, C. K., S. Jain, A. M. Strickland, A. Gupta, and J. Milbrandt. 2006. Glial cell-line derived neurotrophic factor-mediated RET signaling regulates spermatogonial stem cell fate. Biol Reprod 74 (2):314-21.

Ning, L., E. Goossens, M. Geens, D. Van Saen, I. Van Riet, D. He, and H. Tournaye. 2010. Mouse spermatogonial stem cells obtain morphologic and functional characteristics of hematopoietic cells in vivo. Hum Reprod 25 (12):3101-9.

Oatley, J. M., M. R. Avarbock, and R. L. Brinster. 2007. Glial cell line-derived neurotrophic factor regulation of genes essential for self-renewal of mouse spermatogonial stem cells is dependent on Src family kinase signaling. J Biol Chem 282 (35):25842-51.

Oatley, J. M., M. R. Avarbock, A. I. Telaranta, D. T. Fearon, and R. L. Brinster. 2006. Identifying genes important for spermatogonial stem cell self-renewal and survival. Proc Natl Acad Sci U S A 103 (25):9524-9.

Oatley, J. M., and R. L. Brinster. 2006. Spermatogonial stem cells. Methods Enzymol 419:259-82.

Oatley, J. M., and R. L. Brinster. 2008. Regulation of spermatogonial stem cell self-renewal in mammals. Annu Rev Cell Dev Biol 24:263-86.
Oatley, M. J., K. E. Racicot, and J. M. Oatley. 2010. Sertoli cells dictate spermatogonial stem cell niches in the mouse testis. *Biol Reprod* 84 (4):639-45.

Ogawa, T., M. Ohmura, Y. Yumura, H. Sawada, and Y. Kubota. 2003. Expansion of murine spermatogonial stem cells through serial transplantation. *Biol Reprod* 68 (1):316-22.

Ohmichi, H., U. Koshimizu, K. Matsumoto, and T. Nakamura. 1998. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. *Development* 125 (7):1315-24.

Okita, K., M. Nakagawa, H. Hyenjong, T. Ichisaka, and S. Yamanaka. 2008. Generation of mouse induced pluripotent stem cells without viral vectors. *Science* 322 (5903):949-53.

Oottamasathien, S., Y. Wang, K. Williams, O. E. Franco, M. L. Wills, J. C. Thomas, K. Saba, A. R. Sharif-Afshar, J. H. Makari, N. A. Bhowmick, R. T. DeMarco, S. Hipkens, M. Magnuson, J. W. Brock, 3rd, S. W. Hayward, J. C. th Pope, and R. J. Matusik. 2007. Directed differentiation of embryonic stem cells into bladder tissue. *Dev Biol* 304 (2):556-66.

Petersen, B. E., W. C. Bowen, K. D. Patrene, W. M. Mars, A. K. Sullivan, N. Murase, S. S. Boggs, J. S. Greenberger, and J. P. Goff. 1999. Bone marrow as a potential source of hepatic oval cells. *Science* 284 (5417):1168-70.

Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. *Science* 284 (5411):143-7.

Polo, J. M., S. Liu, M. E. Figueroa, W. Kulalert, S. Eminli, K. Y. Tan, E. Apostolou, M. Stadtfeld, Y. Li, T. Shioda, S. Natesan, A. J. Wagers, A. Melnick, T. Evans, and K. Hochedlinger. 2010. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nat Biotechnol* 28 (8):848-55.

Reinisch, A., and D. Strunk. 2009. Isolation and animal serum free expansion of human umbilical cord derived mesenchymal stromal cells (MSCs) and endothelial colony forming progenitor cells (ECFCs). *J Vis Exp* (32).

Safford, K. M., K. C. Hicok, S. D. Safford, Y. D. Halvorsen, W. O. Wilkison, J. M. Gimble, and H. E. Rice. 2002. Neurogenic differentiation of murine and human adipose-derived stromal cells. *Biochem Biophys Res Commun* 294 (2):371-9.

Sariola, H., and T. Immonen. 2008. GDNF maintains mouse spermatogonial stem cells in vivo and in vitro. *Methods Mol Biol* 450:127-35.

Seandel, M., D. James, S. V. Shmelkov, I. Falcatori, J. Kim, S. Chava, D. S. Scherr, F. Zhang, R. Torres, N. W. Gale, G. D. Yancopoulos, A. Murphy, D. M. Valenzuela, R. M. Hobbs, P. P. Pandolfi, and S. Rafii. 2007. Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. *Nature* 449 (7160):346-50.

Shambrot, M. J., J. Axelman, S. Wang, E. M. Bugg, J. W. Littlefield, P. J. Donovan, P. D. Blumenthal, G. R. Huggins, and J. D. Gearhart. 1998. Derivation of pluripotent stem cells from cultured human primordial germ cells. *Proc Natl Acad Sci U S A* 95 (23):13726-31.

Simon, L., G. C. Ekman, T. Garcia, K. Carnes, Z. Zhang, T. Murphy, K. M. Murphy, R. A. Hess, P. S. Cooke, and M. C. Hofmann. 2010. ETV5 regulates sertoli cell chemokines involved in mouse stem/progenitor spermatogonia maintenance. *Stem Cells* 28 (10):1882-92.
Spermatogonial Stem Cells: An Alternate Source of Pluripotent Stem Cells for Regenerative Medicine

Simon, L., G. C. Ekman, N. Kostereva, Z. Zhang, R. A. Hess, M. C. Hofmann, and P. S. Cooke. 2009. Direct transdifferentiation of stem/progenitor spermatogonia into reproductive and nonreproductive tissues of all germ layers. Stem Cells 27 (7):1666-75.

Simon, L., R. A. Hess, and P. S. Cooke. 2010. Spermatogonial stem cells, in vivo transdifferentiation and human regenerative medicine. Expert Opin Biol Ther 10 (4):519-30.

Stadtfeld, M., E. Apostolou, H. Akutsu, A. Fukuda, P. Follett, S. Natesan, T. Kono, T. Shioda, and K. Hochedlinger. 2010. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465 (7295):175-81.

Stadtfeld, M., and K. Hochedlinger. 2010. Induced pluripotency: history, mechanisms, and applications. Genes Dev 24 (20):2239-63.

Stadtfeld, M., M. Nagaya, J. Utikal, G. Weir, and K. Hochedlinger. 2008. Induced pluripotent stem cells generated without viral integration. Science 322 (5903):945-9.

Stevens, L. C. 1964. Experimental Production of Testicular Teratomas in Mice. Proc Natl Acad Sci U S A 52:654-61.

Streckfuss-Bomeke, K., A. Vlasov, S. Hulsmann, D. Yin, K. Nayernia, W. Engel, G. Hasenfuss, and K. Guan. 2009. Generation of functional neurons and glia from multipotent adult mouse germ-line stem cells. Stem Cell Res 2 (2):139-54.

Strulovici, Y., P. L. Leopold, T. P. O'Connor, R. G. Pergolizzi, and R. G. Crystal. 2007. Human embryonic stem cells and gene therapy. Mol Ther 15 (5):850-66.

Takahashi, K., K. Okita, M. Nakagawa, and S. Yamanaka. 2007. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2 (12):3081-9.

Takahashi, K., K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (5):861-72.

Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (4):663-76.

Taylor, R. A., P. A. Cowin, G. R. Cunha, M. Pera, A. O. Trounson, J. Pedersen, and G. P. Risbridger. 2006. Formation of human prostate tissue from embryonic stem cells. Nat Methods 3 (3):179-81.

Taylor, R. A., H. Wang, S. E. Wilkinson, M. G. Richards, K. L. Britt, F. Vaillant, G. J. Lindeman, J. E. Visvader, G. R. Cunha, J. St John, and G. P. Risbridger. 2009. Lineage enforcement by inductive mesenchyme on adult epithelial stem cells across developmental germ layers. Stem Cells 27 (12):3032-42.

Tegelenbosch, R. A., and D. G. de Rooij. 1993. A quantitative study of spermatogonial multiplication and stem cell renewal in the C3H/101 F1 hybrid mouse. Mutat Res 290 (2):193-200.

Thomas, E. D., H. L. Lochte, Jr., J. H. Cannon, O. D. Sahler, and J. W. Ferreebee. 1959. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38:1709-16.

Thomson, A. A., G. R. Cunha, and P. C. Marker. 2008. Prostate development and pathogenesis. Differentiation 76 (6):559-64.

Thomson, J. A., J. Itskovitz-Eldor, S. S. Shapiro, M. A. Waknitz, J. J. Swiergiel, V. S. Marshall, and J. M. Jones. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282 (5391):1145-7.
Tyagi, G., K. Carnes, C. Morrow, N. V. Kostereva, G. C. Ekman, D. D. Meling, C. Hostetler, M. Griswold, K. M. Murphy, R. A. Hess, M. C. Hofmann, and P. S. Cooke. 2009. Loss of Etv5 decreases proliferation and RET levels in neonatal mouse testicular germ cells and causes an abnormal first wave of spermatogenesis. *Biol Reprod* 81 (2):258-66.

Wobus, A. M., and K. R. Boheler. 2005. Embryonic stem cells: prospects for developmental biology and cell therapy. *Physiol Rev* 85 (2):635-78.

Wu, D. C., A. S. Boyd, and K. J. Wood. 2007. Embryonic stem cell transplantation: potential applicability in cell replacement therapy and regenerative medicine. *Front Biosci* 12:4525-35.

Ying, Y., X. M. Liu, A. Marble, K. A. Lawson, and G. Q. Zhao. 2000. Requirement of Bmp8b for the generation of primordial germ cells in the mouse. *Mol Endocrinol* 14 (7):1053-63.

Yu, J., M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, Slukvin, II, and J. A. Thomson. 2007. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318 (5858):1917-20.

Zechner, U., J. Nolte, M. Wolf, K. Shirneshan, N. E. Hajj, D. Weise, B. Kaltwasser, A. Zovoilis, T. Haaf, and W. Engel. 2009. Comparative methylation profiles and telomerase biology of mouse multipotent adult germline stem cells and embryonic stem cells. *Mol Hum Reprod* 15 (6):345-53.

Zedou, M., A. Briquet, B. Relic, C. Josse, M. G. Malaise, A. Gothot, C. Lechanteur, and Y. Beguin. 2010. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. *Cell Biol Int* 34 (7):693-701.

Zhao, T., Z. N. Zhang, Z. Rong, and Y. Xu. 2011. Immunogenicity of induced pluripotent stem cells. *Nature* 474:212-5

Zheng, K., X. Wu, K. H. Kaestner, and P. J. Wang. 2009. The pluripotency factor LIN28 marks undifferentiated spermatogonia in mouse. *BMC Dev Biol* 9:38.

Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S. 2009. Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 4 (5):381-384.

Zovoilis, A., J. Nolte, N. Drusenheimer, U. Zechner, H. Hada, K. Guan, G. Hasenfuss, K. Nayernia, and W. Engel. 2008. Multipotent adult germline stem cells and embryonic stem cells have similar microRNA profiles. *Mol Hum Reprod* 14 (9):521-9.

Zuk, P. A., M. Zhu, H. Mizuno, J. Huang, J. W. Futrell, A. J. Katz, P. Benhaim, H. P. Lorenz, and M. H. Hedrick. 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 7 (2):211-28.

Zwaka, T. P., and J. A. Thomson. 2005. A germ cell origin of embryonic stem cells? *Development* 132 (2):227-33.
When most types of human tissue are damaged, they repair themselves by forming a scar - a mechanically strong 'patch' that restores structural integrity to the tissue without restoring physiological function. Much better, for a patient, would be like-for-like replacement of damaged tissue with something functionally equivalent: there is currently an intense international research effort focused on this goal. This timely book addresses key topics in tissue regeneration in a sequence of linked chapters, each written by world experts; understanding normal healing; sources of, and methods of using, stem cells; construction and use of scaffolds; and modelling and assessment of regeneration. The book is intended for an audience consisting of advanced students, and research and medical professionals.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Liz Simon, Marie-Claude Hofmann and Paul S. Cooke (2012). Spermatogonial Stem Cells: An Alternate Source of Pluripotent Stem Cells for Regenerative Medicine, Tissue Regeneration - From Basic Biology to Clinical Application, Prof. Jamie Davies (Ed.), ISBN: 978-953-51-0387-5, InTech, Available from: http://www.intechopen.com/books/tissue-regeneration-from-basic-biology-to-clinical-application/spermatogonial-stem-cells-an-alternate-source-of-pluripotent-stem-cells-for-regenerative-medicine
